Certara, Inc.(CERT) Stock Research - Grey Stern Research
Loading...

Certara, Inc. (CERT) Stock Analysis

$10.99 (-3.34%)

CERT Financial Performance


Use the table below to view Certara, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $11.37 -
52 Week Low $10.35 -
52 Week High $19.87 -
Market Cap $1.8 Billion 5/12
Gross Margin 43% 7/12
Profit Margin -13% 9/12
EBITDA margin 15% 5/12
Q2 - 2024 Revenue $93.3 Million 9/12
Q2 - 2024 Earnings -$12.6 Million 9/12
Q2 - 2024 Free Cash Flow $3.7 Million 5/12
Trailing 4 Quarters Revenue $363.6 Million 9/12
Trailing 4 Quarters Earnings -$78.7 Million 8/12
Quarterly Earnings Growth -367% 9/12
Annual Earnings Growth -996% 10/12
Quarterly Revenue Growth 3% 7/12
Annual Revenue Growth 1% 11/12
Cash On Hand $224.6 Million 4/12
Short Term Debt $7.7 Million 8/12
Long Term Debt $293.7 Million 6/12

Certara, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Certara, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 5/12
PS 5.03 2/12
PB 1.75 8/12
PC 8.14 8/12
Liabilities to Equity 0.48 10/12
ROA -0.05 10/12
ROE -0.08 10/12
Current Ratio 3.10 2/12
Quick Ratio 0.45 5/12
Long Term Debt to Equity 0.28 8/12
Debt to Equity 0.30 9/12
Burn Rate 8.56 2/12
Cash to Cap 0.12 5/12
CCR -0.29 8/12
EV to EBITDA 141.23 3/12
EV to Revenue 5.27 3/12

Company Details

Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

CEO: Dr. Edmundo Muniz

Website: https://www.certara.com

Address: 100 Overlook Center Princeton, NJ

Exchange: NASDAQ Global Select

Industry: Health Information Services

Certara, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Certara, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
HealthEquity, Inc. HQY $6.9 Billion
Evolent Health, Inc. EVH $3.1 Billion
R1 RCM Inc. RCM $6.0 Billion
Computer Programs and Systems, Inc. CPSI $133.7 Million
HealthStream, Inc. HSTM $905.6 Million
Health Catalyst, Inc. HCAT $477.7 Million
National Research Corporation NRC $503.2 Million
NextGen Healthcare, Inc. NXGN $1.6 Billion
Agiliti, Inc. AGTI $1.4 Billion
Privia Health Group, Inc. PRVA $2.1 Billion
CareMax, Inc. CMAX $6.3 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
CERT Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 93.3 Million -$12.6 Million
Q1 2024 $ 96.7 Million -$4.7 Million
Q4 2023 $ 88.0 Million -$12.5 Million
Q3 2023 $ 85.6 Million -$49.0 Million
Q2 2023 $ 90.5 Million $4.7 Million
Q1 2023 $ 90.3 Million $1.4 Million
Q4 2022 $ 86.6 Million $9.2 Million
Q3 2022 $ 84.7 Million $3.9 Million

View All

CERT Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $224.6 Million $1.5 Billion $312.6 Million $1.0 Billion
Q1 2024 $224.8 Million $1.5 Billion $306.8 Million $1.1 Billion
Q4 2023 $235.0 Million $1.6 Billion $298.2 Million $1.0 Billion
Q3 2023 $272.3 Million $1.5 Billion $303.4 Million $1.1 Billion
Q2 2023 $245.2 Million $1.6 Billion $300.4 Million $1.1 Billion
Q1 2023 $244.1 Million $1.6 Billion $306.6 Million $1.1 Billion
Q4 2022 $236.6 Million $1.6 Billion $308.1 Million $1.1 Billion
Q3 2022 $210.5 Million $1.5 Billion $305.4 Million $1.1 Billion

View All

CERT Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 $3.7 Million -$6.1 Million -$177,000
Q1 2024 $718,000 -$3.6 Million -$10.2 Million
Q4 2023 $32.5 Million $9.2 Million -$37.4 Million
Q3 2023 $27.4 Million -$4.0 Million $24.1 Million
Q2 2023 $13.9 Million -$4.2 Million $972,000
Q1 2023 $7.2 Million -$2.7 Million $7.6 Million
Q4 2022 $32.3 Million -$3.2 Million $25.9 Million
Q3 2022 $23.6 Million -$390,000 $15.5 Million

View All